PharmNovo announces positive Phase I results for neuropathic pain management drug PN6047
Swedish pharmaceutical company PharmNovo is proud to announce the positive final results from the Phase I trial of its neuropathic pain drug candidate, PN6047. This trial demonstrates the safety and tolerability of PN6047, underscoring its potential as an innovative option in pain management.PharmNovo, a clinical-stage pharmaceutical company, focuses on the development of safe and effective treatments for neuropathic pain. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 was